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BACKGROUND: Pazopanib has activity in relapsed non-adipocytic soft-tissue sarcomas (STS). A series of serum cytokines and angiogenic
factors (CAFs) at baseline and changes in soluble vascular endothelial growth factor receptor-2 (sVEGFR2) or placental-derived
growth factor (PlGF) levels during treatment were explored for their association with outcome.
METHODS: Twenty-three baseline CAFs, and sVEGFR2 and PlGF changes were measured in 85 and 32 patients, respectively.
Associations between baseline CAF levels and efficacy parameters, plus between-week 12 sVEGFR2 and PlGF levels and pazopanib-
specific toxicities were investigated.
RESULTS: At baseline, low interleukin (IL)-12 p40 subunit and MPC3 levels were associated with better progression-free survival (PFS)
at 12 weeks (PFS12wks), low basic nerve growth factor and hepatocyte growth factor with a better PFS, and low inter-cellular
adhesion molecule-1 and IL-2 receptor alpha with prolonged overall survival (OS; all Po0.05). Pazopanib decreased sVEGFR2
and increased PlGF levels. Low sVEGFR2 and high PlGF levels at week 12 were associated with higher-grade hypertension, with TSH
elevations and with poorer PFS12wks, and OS (both Po0.05).
CONCLUSION: Several baseline CAFs were related to outcome parameters. Low sVEGFR2 and high PlGF at week 12 associate with
several pazopanib-specific toxicities and poorer efficacy. If confirmed, these factors may be used as early markers for response to and
toxicity from pazopanib, enabling further individualisation of STS treatment.
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The group of adult soft-tissue sarcomas (STS) is a rare group of
tumours comprising more than 40 entities. Patients with advanced
STS have a poor prognosis, and until recently, only doxorubicin
and ifosfamide had shown consistent activity (Sleijfer et al, 2005;
Tascilar et al, 2007). Fortunately, with an increasing recognition
that these histological subtypes have diverse natural histories and
treatment responses, an increasing number of new systemic
treatments based on histology are now being utilised, including
imatinib for gastro-intestinal stromal tumours (GISTs; Verweij
et al, 2004), taxanes for angiosarcomas (Fata et al, 1999),
and trabectedin for liposarcomas and leiomyosarcomas (Demetri
et al, 2009). Undoubtedly though, the vast majority of advanced
non-GISTs STS patients continue to face a poor prognosis. The
median overall survival (OS) for patients with metastatic STS does
not exceed 12 months and this statistic has not changed in more than
two decades, clearly underscoring the need for effective novel agents.
Recently, the European Organization of Research and Treatment
of Cancer, Soft Tissue, and Bone Sarcoma Group (EORTC-STBSG)
performed a phase II study of pazopanib in patients with relapsed
or refractory STS (Sleijfer et al, 2009). Pazopanib is a tyrosine-
kinase inhibitor (TKI) targeting several factors, among which
are the vascular endothelial growth factor receptors (VEGFRs), the
platelet-derived growth factor receptors, and the c-kit. Stratifica-
tion for histological subtype was undertaken and clinically
significant anti-tumour activity was seen in those patients with
synovial sarcomas, leiomyosarcomas, and other eligible STS
entities, but not for those with adipocytic sarcomas (Sleijfer
et al, 2009). On the basis of this study, a placebo-controlled phase
III study in non-adipocytic STS was initiated by the EORTC-
STBSG group and showed a three-fold prolongation in progres-
sion-free survival (PFS; Van der Graaf et al, 2011).
The role of biomarkers for either toxicity or efficacy has become
increasingly important in allowing ‘personalisation’ of particular
treatment types for many cancers. As with other VEGFR–TKIs,
pazopanib’s main mechanism of action is thought to be through
impacting tumour angiogenesis (Hamberg et al, 2010). Therefore,
as part of the phase II study of pazopanib in advanced STS,
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an exploratory translation research component was incorporated
to attempt to identify cytokines and angiogenic factors (CAFs)
determined at baseline that are associated with outcome to
pazopanib in STS. In addition, VEGFR–TKIs have been shown to
decrease soluble VEGFR2 (sVEGFR2) and increase placental-
derived growth factor (PlGF) blood levels (Rini et al, 2008;
Hanrahan et al, 2009a; Bass et al, 2010; Murukesh et al, 2010;
Nikolanikos et al, 2010), and consequently, these markers
have been suggested as pharmacodynamic markers for VEGFR
inhibition. We therefore also analysed whether changes in PlGF
and sVEGFR2 correlate with the occurrence of toxicities thought to
be specific for pazopanib and with survival outcome.
METHODS
Patients and study design
The details of the multi-centre, single-arm phase II study of
pazopanib in relapsed or refractory STS (EORTC 62043, NCT000
297258) have been previously published (Sleijfer et al, 2009).
Briefly, patients with intermediate or high-grade advanced STS,
ineligible for further chemotherapy, or having received no more
than two prior cytotoxic agents in the advanced setting were
eligible. Patients had documented progression before study entry,
adequate performance status, and a good organ function.
Pazopanib was given a dose of 800mg daily until progression or
unacceptable toxicity. The primary end point was progression-free
rate at 12 weeks. Secondary end points included response, safety,
and OS. Given the great heterogeneity of the different STS entities,
four different strata were studied: adipocytic STS, leiomyosarco-
mas, synovial sarcomas, and other eligible STS types. A Simon
two-stage design was applied (P1: 40%; P0: 20%; a¼ b¼ 0.1) to
each stratum. In total, 142 patients were enroled. The adipocytic
STS stratum was closed after the first stage, given insufficient
activity according to study protocol, whereas in the other three
cohorts, pazopanib yielded anti-tumour activity considered
worthwhile to be further explored according to the pre-specified
criteria (Sleijfer et al, 2009). The study was approved by the
institutional review boards of all participating centres and was
conducted in agreement with the Declaration of Helsinki and the
International Conference on Harmonization of Good Clinical
Practice guidelines. All patients gave written informed consent to
participate. Consent for blood sampling for biomarker analysis
was optional. There was a separate consent for participation in the
translational research part of the study and this part of the study
was voluntary.
Blood sample collection and analyses
Venous serum samples were taken at baseline and at 12 weeks after
treatment start, and stored at  20 1C until analysis. Analysis of
serum samples was performed blinded to patient outcome.
Twenty-three different CAFs were determined at baseline using a
commercially available multiplex bead assay (BioRab Laboratories,
Inc., Veenendaal, The Netherlands/Minneapolis, MN, USA)
according to the manufacturers’ instructions. In addition, PlGF
and sVEGFR2 were measured at baseline and at the time of
evaluation of the primary end point (12 weeks after treatment
start) by enzyme-linked immunosorbent assay (DPG00 and
DVR200, respectively) according to the manufacturers’ instruction
(R&D systems Europe, Abingdon, UK).
Statistical methods
The aim of this translational research sub-study was to generate
hypotheses that could be further validated in future trials
with pazopanib in STS and so, these analyses are essentially
exploratory.
With respect to the CAF determined at baseline, we aimed to
identify biomarkers that could predict ‘success of therapy’,
defined as being PFS at 12 weeks (PFS12wks), which was
the primary end point of the clinical trial. Secondary objectives
included correlation with other efficacy end points, PFS, and
OS. The CAF analytes were first analysed as continuous
variables; measurements below the detection level were con-
ventionally assigned a value equal to half of the detection
threshold. For illustration of the results, significant factors were
subsequently categorised according to quartiles (rounded
values).
In addition to baseline, sVEGFR2 and PIGF serum levels
were determined at 12 weeks after treatment start. We analysed
whether the specific pazopanib toxicities hypertension and
hypopigmentation could be predicted by absolute levels and/or
changes in these two factors. Secondary objectives included
correlation with other toxicities (fatigue, diarrhoea, nausea,
and TSH elevation), and with the efficacy end points PFS12wks,
PFS, and OS. Analyses were done for the serum level at baseline,
the serum level at 12 weeks, and the ratio between the two
levels. All these three determinants were initially explored as
continuous variables and subsequently categorised as binary
variables (using the median value as cut-off) for illustration of
the results.
The categorical data mentioned in this report were summarised
by frequencies and percentages, the continuous covariates by
median, range, and numbers of observations. Survival data were
plotted using the Kaplan–Meier method. Toxicity was graded
according to the NCI-CTCAE version 3.0 (http://ctep.cancer.gov).
Univariate analysis was performed among baseline covariates
(CAFs) by logistic regression (Wald test) for PFS12wks, and by Cox
regression (Wald test) for PFS and OS, when analysed as
continuous variables. The statistical significance was set at 0.05
based on a two-sided statistical test. Subsequently, multivariate
regression models were built; a logistic model for PFS12wks and Cox
models for OS and PFS including all factors with a significant or
borderline prognostic value in the univariate analyses. Non-
significant factors were removed according to a backward selection
procedure with the statistical significance set at 0.05 based on a
two-sided test. The univariate analysis was the first step of the
process aiming at rejecting the less significant variables from the
multivariate regression models.
Outcomes are reported as odds ratios (OR; PFS12wks) or hazard
ratios (HR; PFS and OS) with confidence intervals (CIs).
Correlations between baseline CAFs and PFS12wks were subse-
quently illustrated in bar charts, and correlations with PFS and OS
in Kaplan–Meier curves; for this purpose, the baseline variables
were categorised.
Pearson’s and Spearman’s correlation coefficients were used to
assess the relationship between sVEGFR2 and PIGF levels
(continuous variables) and toxicities. Results were illustrated as
bar charts, using binary variables.
Statistical Analysis Software version 9.2 (SAS Institute, Cary,
NC, USA) was used for statistical analyses.
RESULTS
Patient population
A total of 142 patients were recruited in the clinical trial from 15
November 2005 to 16 May 2007. The CAF profile (at baseline)
could be measured in 85 of those patients. The sVEGFR2 and PlGF
levels were measured in 32 and 31 patients, respectively, at baseline
and at 12 weeks after treatment initiation. There were no
significant differences between the characteristics of the 142
patients comprising the original study population compared with
those incorporated in this side-study (Table 1).
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Baseline CAF profile
Table 2 depicts the distribution of the 23 markers measured at
baseline. Univariate logistic regression models were built to
explore the possible prognostic value of the different marker
levels for PFS12wks. Only two factors, the interleukin (IL)-12 p40
subunit (IL12p40; OR 0.999; 95% CI 0.998–1.000 (P¼ 0.0305)) and
monocyte chemotactic protein-3 (OR 0.978; 95% CI 0.959–0.997
(P¼ 0.0271)), were significant at the 0.05 confidence level. Low
levels of these factors were associated with a higher chance of
being progression-free at 12 weeks. However, because of multiple
testing, the false discovery rate adjusting for 23 tests was around
50%. These two factors were highly correlated and both lost their
significance in a multivariate model.
Two parameters were significantly correlated with prolonged
PFS; low levels of hepatocyte growth factor (HGF; HR 1.000;
95% CI 1.000–1.000 (P¼ 0.0079)) and basic nerve growth factor
(bNGF; HR 1.167; 95% CI 1.049–1.299 (P¼ 0.0044)). Again,
because of multiple testing, the false discovery rate was relatively
high at around 20%. These two factors kept a significant
prognostic value in the multivariate model. Results of these two
correlations are shown as a Kaplan–Meier estimate of PFS in
marker categories (Figure 1A and B).
Similarly, two baseline CAF levels demonstrated significant
correlation with OS; low levels of IL-2 receptor alpha (IL2ra; HR
1.002; 95% CIs 1.001–1.003 (P¼ 0.0078)) and inter-cellular
adhesion molecule-1 (ICAM-1; HR 1.000; 95% CIs 1.000–1.000
(P¼ 0.0072)) were associated with prolonged survival. Again, the
false discovery rate adjusting for 23 tests was rather high around
20%. Both factors were highly correlated and lost their significance
in the multi-variate Cox model. Figure 1C and D depicts the OS
in four markers categories.
Placental-derived growth factor and sVEGFR2 at week 12
The sVEGFR2 (32 patients) and PIGF (31 patients) serum levels
were measured before treatment start and at the time of evaluation
of the primary end point (end of week 12). It should be noted that
those patients are not fully representative of the study population.
Patients had to be alive and under protocol therapy to take the
second sample. As a result, patients who died or progressed before
week 12 were automatically excluded from this analysis. Conse-
quently, outcome in terms of PFS and OS was better in this group
in comparison with the whole population or with the patients
included in the analysis for the CAF profile determined at baseline
(median PFS: 4.2 months vs 3.0 months and median OS 13.5
months vs 10.5 months).
As shown in Table 3, sVEGFR2 decreased during treatment,
whereas PlGF increased. The PIGF levels were below the detection
threshold in 20 patients at baseline as a consequence of which the
week 12/baseline ratio could not be precisely computed. Therefore,
this parameter was not further analysed for PlGF.
The sVEGFR2 levels at week 12 were correlated to baseline
levels (Pearson’s correlation coefficient 0.537 (P¼ 0.0015 )). For all
patients, week 12 levels were below the initial level. The PIGF levels
Table 1 Patients’ and disease characteristics
All patients
(N¼ 142)
CAF study
(N¼ 85)
sVEGFR2/PlGF
study (N¼ 32)
N (%) N (%) N (%)
Age (years)
Median 51.4 51.7 46.0
Range 18.5–79.3 18.5–77.3 18.5–73.4
Sex
Male 71 (50.0) 43 (50.6) 14 (43.8)
Female 71 (50.0) 42 (49.4) 18 (56.3)
Performance status (WHO)
0 72 (50.7) 42 (49.4) 20 (62.5)
1 70 (49.3) 43 (50.6) 12 (37.5)
Time since diagnosis (d)
Median 872.5 895.0 878.5
Range 90.0–10481.0 90.0–7488.0 189.0–7488.0
Tumour grade
Low 7 (4.9) 3 (3.5) 3 (9.4)
Intermediate 67 (47.2) 42 (49.4) 13 (40.6)
High 65 (45.8) 39 (45.9) 16 (50.0)
Unknown 3 (2.1) 1 (1.2) 0 (0.0)
Histology
Adipocytic (LIP) 19 (13.4) 10 (11.8) 3 (9.4)
Fibroblastic 5 (3.5) 4 (4.7) 2 (6.3)
Fibrohistiocytic (MFH) 4 (2.8) 0 (0.0) 0 (0.0)
Smooth muscles (LMS) 42 (29.6) 27 (31.8) 9 (28.1)
Skeletal muscle 1 (0.7) 1 (1.2) 0 (0.0)
Vascular 5 (3.5) 4 (4.7) 1 (3.1)
Uncertain different. 45 (31.7) 26 (30.6) 12 (37.5)
MPNST 5 (3.5) 2 (2.4) 2 (6.3)
Malignant solitary fibrous 3 (2.1) 2 (2.4) 2 (6.3)
Undifferentiated NOS 11 (7.7) 8 (9.4) 1 (3.1)
GIST (ineligible) 1 (0.7) 1 (1.2) 0 (0.0)
Mesothelioma (ineligible) 1 (0.7) 0 (0.0) 0 (0.0)
Abbreviations: CAF¼ cytokines and angiogenic factor; GIST¼ gastro-intestinal
stromal tumour; LIP¼ liposarcoma; LMS¼ leiomyosarcoma; MFH¼malignant fibrous
histiocytoma; MPNST¼malignant peripheral nerve sheath tumour; NOS¼ not
otherwise specified; PlGF¼ placental-derived growth factor; sVEGFR¼ soluble vascular
endothelial growth factor receptor; WHO¼World Health Organisation.
Table 2 Distribution of the 23 CAF markers at baseline (all concentrations
are in pgml 1)
Marker N Minimum Maximum Median
Detection
threshold
Nro
thresh
IL1a 85 2.5 15.2 2.5 5 79
IL2ra 85 78 1258 344
IL3 85 50a 613 188 100 28
IL12p40 85 284 2524 1215
IL16 85 61 2124 243
IL18 85 45 724 110
CTACK 85 80 3585 1280
GROa 85 117 645 225
HGF 85 551 15 466 1330
ICAM-1 85 21 281 275 798 82 786
IFNa2 85 140 376 236
LIF 85 10.0a 535 10.0 20 52
MCP3 85 4.5a 105 48 9 1
MCSF 85 40 1130 94
XMIF 85 138 100 000 2144
XMIG 85 135 4451 701
bNGF 85 2.0a 9.5 2.0 4 50
SCF 85 10.0a 656 156 20 1
SCGFb 85 2759 200 000 53 267
SDF1a 85 438 73 250 981
TNFb 85 4.0a 103 19 8 14
TRAIL 85 114 1100 520
VCAM1 85 1464 280 068 96161
Abbreviations: bNGF¼ basic nerve growth factor; CAF¼ cytokines and angiogenic
factor; HGF¼ hepatocyte growth factor; ICAM-1¼ inter-cellular adhesion
molecule-1; IFNa2¼ interferon alpha-2; IL1a¼ interleukin-1 alpha; IL2ra¼ IL-2
receptor alpha; IL12p40¼ IL-12 p40 subunit; MCP3¼monocyte chemotactic
protein-3; MCSF¼macrophage colony-stimulating factor; TNFb¼ tumour necrosis
factor beta; TRAIL¼TNF-related apoptosis-inducing ligand; VCAM1¼ vascular cell
adhesion protein-1. aBelow the detection threshold.
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at week 12 were weakly correlated to baseline levels, but this may
be due to the large proportion of values below the detection
threshold at baseline. There was no correlation between the
baseline values of sVEGFR2 and PIGF; however, the week 12 levels
of the two markers showed a strong, inverse correlation (Pearson’s
correlation coefficient  0.81156 (Po0.001; Figure 2). There was
no apparent correlation of the initial marker levels with other
baseline characteristics such as age, gender, performance score,
site of primary tumour, time since diagnosis, histology of the
primary tumour, or tumour grade (data not shown).
To assess the correlation of these markers with hypertension,
both the Pearson’s (parametric) and Spearman’s (non parametric)
correlation coefficient were computed. Both analyses showed that
hypertension was not correlated to the baseline marker levels,
but was highly correlated to the marker levels at week 12. Higher
grades of hypertension were observed for patients with low
sVEGFR2 levels at week 12 (Pearson’s correlation coefficient
 0.57282 (P¼ 0.0006); Spearman’s correlation coefficient
 0.57828 (P¼ 0.0005)) and high PIGF levels at week 12 (Pearson’s
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Figure 1 Progression-free survival by baseline bNGF (A) and baseline HGF (B), together with overall survival by baseline ICAM-1 (C) and IL2ra (D).
For this analysis, marker levels have been categorised, according to ‘rounded’ quartiles of their distribution. Results therefore slightly differ from those of the
Cox regression analysis.
Table 3 PlGF and sVEGFR2 levels at baseline and week 12 of treatment
(all concentrations are in pgml 1)
Serum level of sVEGFR2 Serum level of PlGF
Number of observations 32 31
Serum level at baseline
Median 10 605a 7.0a
Range 6901–14 898 7.0–360a
Mean 10 690 23
Standard deviation 1741 64
Serum level at week 12
Median 6973 49
Range 3193–10520 7.0–356a
Mean 6821 122
s.d. 1973 120
Ratio (week 12/baseline)
Median 0.70 n.d.
Range 0.37–0.94 n.d.
Mean 0.64 n.d.
s.d. 0.16 n.d.
Abbreviations: n.d.¼ not determined; PlGF¼ placental-derived growth factor;
sVEGFR¼ soluble vascular endothelial growth factor receptor. Ratio week
12/baseline was not determined for PlGF, as 20 patients had PlGF levels
below threshold at baseline. aBelow detection threshold.
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Figure 2 Scatterplot of PlGF and sVEGFR2 levels at week 12.
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correlation coefficient 0.61287 (P¼ 0.0002); Spearman’s correla-
tion coefficient 0.53414 (P¼ 0.0020)). For sVEGFR2, the week
12/baseline ratio was also correlated, but weaker (Pearson’s
correlation coefficient  0.50304 (P¼ 0.0033); Spearman’s correla-
tion coefficient  0.49536 (P¼ 0.0039). Figure 3 illustrates the
correlation between marker levels at week 12 and the grade of
hypertension; for this graph, the marker levels were dichotomised
according to the median. As sVEGFR2 and PlGF levels at week
12 were strongly correlated, also the combinations were explored.
Those patients with a PlGF above and a sVEGFR2 below the
respective medians had the highest grades of hypertension.
With respect to the other VEGFR–TKI-specific toxicity taken as
primary end point in this study, hypopigmentation, no correlation
with sVEGFR2 or PlGF levels was found. Also none of the other
toxicities (fatigue, diarrhoea, and nausea) were correlated
with these two markers at both time points, except for TSH
elevation. Low sVEGR2 (Pearson’s correlation coefficient
 0.50632 (P¼ 0.007); Spearman’s correlation coefficient
 0.50216 (P¼ 0.0076)) and high PlGF levels (Pearson’s correla-
tion coefficient 0.47833 (P¼ 0.0134); Spearman’s correlation
coefficient 0.54415 (P¼ 0.0041)) were associated with higher
TSH elevations, indicating compromised thyroid function.
As a secondary end point, the correlations of sVEGFR2 and PlGF
with PFS12wks were assessed. Baseline levels were non-predictive,
but week 12 levels of both markers were significantly correlated
with success rate. High sVEGFR2 and low PlGF were associated
with a more favourable outcome in terms of PFS12wks (OR 0.636;
95% CI 0.413–0.977 (P¼ 0.039)) and (OR 1.081; 95% CI
1.007–1.160 (P¼ 0.0318), respectively) (Figure 4A). In contrast
to PFS, for which no correlation could be found, there was also
a correlation between marker levels at week 12 and OS. For
high sVEGFR2 at week 12, there was a trend for prolonged OS
(sVEGFR2: HR 0.817; 95% CI 0.644–1.037 (P¼ 0.0966), whereas
there was a statistically significant association between low PlGF
levels at week 12 and longer OS (PlGF: HR 1.061; 95% CI
1.025–1.099 (P¼ 0.0009), respectively; Figure 4B and C). Also in a
multivariate model with these two factors, the association between
PIGF levels at week 12 and OS was statistically significant.
DISCUSSION
We have previously reported on the phase II study of clinical
efficacy of pazopanib in pretreated non-adipocytic STS (Sleijfer
et al, 2009). This preliminary evidence has been subsequently
evaluated with a placebo-controlled trial on pazopanib in
pretreated non-adipocytic STS and recruitment has now been
completed. The early data has shown a statistically significant
three-fold prolongation in PFS with pazopanib compared with
placebo (Van der Graaf et al, 2011). In the earlier study, we
explored whether or not we could identify advanced STS patients
likely to benefit from pazopanib on the basis of CAFs determined
before treatment start. Furthermore, we did an exploratory
analysis whether changes in sVEGFR2 and PlGF were associated
with pazopanib-specific adverse events and anti-tumour activity.
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Figure 3 Associations with grade hypertension with sVEGR2 and PlGF
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Figure 4 Association of sVEGFR2 and PlGF levels at week 12, with success rate at week 12 (A), OS by PlGF levels at week 12 (B), and by sVEGFR2 levels
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Of the 23 different CAFs determined at baseline, it appeared that
low IL12p40 and MPC3 levels were associated with better PFS12wks,
low bNGF and HGF with a better PFS, and low ICAM-1 and IL2ra
with prolonged OS. As inhibition of angiogenesis is thought to be
the main mechanism by which pazopanib and other VEGFR–TKIs
exert their anti-tumour activity, baseline factors associated with
outcome may be similar across different tumour types and
VEGFR–TKIs. In line with our finding of low baseline HGF levels
being associated with prolonged PFS, greater tumour shrinkage
and a longer PFS was observed in pazopanib-treated renal cell
carcinoma (RCC) with low baseline HGF (Tran et al, 2010).
In contrast, Nikolinakos et al (2010) found an association between
greater tumour shrinkage and high baseline HGF in pazopanib-
treated non-small cell lung carcinoma (NSCLC) patients . Also our
finding that a low IL2ra was associated with a longer OS is in
contrast to their findings, wherein a high IL2ra level was associated
with greater tumour shrinkage in the same patient cohort
(Nikolinakos et al, 2010). Other baseline factors associated with
outcome with pazopanib in RCC and NSCLC were either not
incorporated in our study (IL-6, IL-8, IL-12, IL-16, E-selectin,
IP-10) or not associated with outcome in STS (SDF-1a, IL2ra, IL-3,
IFNa2, TRAIL, M-CSF, and PlGF; Nikolinakos et al, 2010; Tran
et al, 2010). With respect to VEGFR–TKIs other than pazopanib,
levels of numerous serum factors, in particular VEGF and
sVEGFR2, have been explored for their association with outcome
in various tumour types (Murukesh et al, 2010). In some of these
studies, low baseline levels were associated with a favourable
outcome parameter (Kiura et al, 2008; Rini et al, 2008; Hanrahan
et al, 2009b), but as was seen in our study, no such associations
could be revealed in many other studies (Murukesh et al, 2010).
Altogether, given the fact that none of the factors evaluated was
associated with more than one efficacy parameter in our study,
the high false-discovery rate ranging between 20–50%, and the
inconsistency associations seen for other tumour types and other
VEGFR–TKIs, it can be suspected that the associations in our
study are false-positive ones. Nevertheless, given the potentially
important clinical relevance, the identified associations deserve to
be studied further and will therefore be investigated in the recently
completed placebo-controlled phase III study on pazopanib in
non-adipocytic STS patients.
In addition to baseline CAFs, we explored whether absolute
sVEFR2 and PlGF levels at week 12 after treatment start and/or
changes compared with baseline are associated with pazopanib-
specific-toxicities and with outcome to pazopanib. Previously,
several VEGFR–TKI such as pazopanib, sunitinib, cediranib,
vandetanib, and motesanib have consistently been shown to
decrease sVEGFRs levels and to increase VEGF and PlGF (Drevs
et al, 2005; Rini et al, 2008; Hanrahan et al, 2009a; Bass et al, 2010;
Murukesh et al, 2010; Nikolanikos et al, 2010) and can therefore be
considered a class effect. There is preclinical evidence in sunitinib-
treated tumour-bearing mice for an association between these
changes in VEGF and P1GF levels and tumour response (Ebos
et al, 2007). Therefore, these markers have been proposed
as pharmacodynamic markers for the extent of VEGFR inhibition.
As mentioned, VEGFR inhibition induces increases in both VEGF
and PlGF. As increases in PlGF are more pronounced than those
observed for VEGF (Rini et al, 2008; Nikolanikos et al, 2010), we
chose for the latter in this study. As expected, pazopanib in our
study decreased sVEGR2 and increased PlGF. Consistent with the
hypothesis that these alterations reflect the extent of inhibition
of VEGFR activity, they were associated with the occurrence of
hypertension and TSH elevation, which are both side effects
considered specific for VEGFR–TKIs. This further supports the
hypothesis that changes in these markers may act as pharma-
codynamic markers for VEGFR inhibition. In contrast to our
findings, associations of changes in VEGF and sVEGFR2
with hypertension were not observed in sunitinib-treated RCC
patients (Rini et al, 2008). We could not find any associations
with the occurrence of fatigue and diarrhoea, but it is recognised
that there may be multifactorial causes for these events in
cancer patients, including the disease itself and concomitant
medications.
Whether or not changes in these factors are related to efficacy of
VEGFR–TKIs is of major interest. In a preclinical model, low
sVEGFR2 and high VEGF and PlGF levels, indicative for VEGFR
inhibition, were associated with VEGFR–TKI-mediated anti-
tumour activity (Ebos et al, 2007). In pazopanib-treated NSCLC
patients, an association between a decrease in sVEGFR2 and
tumour shrinkage was found, whereas changes in PlGF or VEGF
were not. Also in a phase I study with AMG706 in advanced cancer
patients, high PlGF and low sVEGFR2 levels were correlated
with greater tumour shrinkage (Rosen et al, 2007). In addition, in a
phase II study on patients with advanced thyroid cancer treated
with motesanib, the response rate was 30% in patients having a
4.7-fold increase in PlGF at 1 week after treatment start compared
with a 3% response rate in those patients with a less profound
increase. Also patients with the strongest decrease in sVEGFR2 had
a higher chance to respond favourably to motesanib (Bass et al,
2010). However, in several other studies exploring VEGFR–TKIs in
various tumour types, changes in these markers were not
associated with outcome (Murukesh et al, 2010). Unexpectedly,
low sVEGFR2 and high PlGF levels at week 12 were not only
associated with a poorer PFS12wks, the primary efficacy end point
in this study, but also with a worse OS. Interestingly and consistent
with our findings, an increase in VEGF at day 8 after initiation of
treatment with the VEGFR–TKI vandetanib was correlated with a
greater risk of progression in NSCLC patients (Hanrahan et al,
2009a). Why effects suggestive of adequate VEGFR inhibition are
related to a poorer outcome to VEGFR inhibitors is unknown.
Lower sVEGFR2 levels, potentially leading to higher circulating
levels of free VEGF, and increased PlGF levels that occur as
response to VEGFR inhibition are probably physiological mechan-
isms to overcome and escape the effects of VEGFR blockade.
Continuous pressure of these increased levels may ultimately lead
to activation of the respective receptors, VEGFR1 and VEGFR2
(Fischer et al, 2008), thereby stimulating tumour cell growth
and angiogenesis, and overcoming the inhibitory effects of
pazopanib. But still, this does not explain why high PlGF and
low sVEGFR2 levels are associated with favourable outcomes in
some studies, whereas the contrary happens in other studies,
including ours. Maybe some tumour types, including STS, are
more sensitive for the proangiogenic and stimulating effects
of PlGF than other malignancies, thereby partially counteracting
the inhibitory effects from VEGFR–TKIs in these particular
tumour types. However, this is purely speculative and required
further study.
Irrespective of the underlying mechanisms, if these associations
can be confirmed, changes in VEGF and PlGF form attractive
markers to determine whether or not a patient benefits from
VEGFR–TKI, and already at an early point during treatment. This
will hold true in particular when such associations exist as early as
day 8 of treatment as was found in vandetanib-treated NSCLC
patients (Hanrahan et al, 2009a). To validate these potentially
important associations, the same markers will be determined at
several time points in various EORTC studies on pazopanib in
diverse tumour types, including the pazopanib phase III trial in
non-adipocytic STS.
In conclusion, several baseline CAFs were related to efficacy of
pazopanib in advanced STS patients. However, these exploratory
results should be interpreted with caution given high false-
discovery rates and inconsistency between the diverse efficacy
parameters. Indicative of VEGFR inhibition, pazopanib decreases
sVEGFR2 and increases PlGF levels, and changes of both factors
are associated with the pazopanib-specific toxicities hypertension
and TSH elevations. The associations of these changes with poorer
efficacy in terms of PFS12wks and OS were unexpected but may be
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of great clinical value. Findings of this study will be validated in the
recently completed phase III study of pazopanib in non-adipocytic
STS. If confirmed, these factors may be used as early markers for
response to pazopanib enabling further individualisation of STS
treatment.
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